{"id":"7e0f6f29-ed19-49ac-97e1-4b3f59425604","arxiv_id":"2603.23082","paper_version":2,"verdict":"UNVERDICTED","confidence":"LOW","novelty_score":3.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"Spatial navigation performance, particularly path integration and wayfinding, correlates with AD biomarkers such as p-tau in cognitively unimpaired at-risk individuals and may enable earlier detection than episodic memory decline.","lead":"This review argues that spatial navigation tasks, especially path integration and wayfinding, detect Alzheimer’s risk earlier than episodic memory tests because they depend on brain circuits hit first by AD pathology. It synthesizes biomarker-linked evidence and positions navigation assessment as a scalable preclinical screening tool.","discovery_kind":"review","skeptic_critique":{"model":"grok-4.5","headline":"No significant objection identified beyond the reader's already-correct abstract-only limitation.","rationale":"The paper is a narrative review whose central claim is a synthesis: spatial navigation (especially path integration and wayfinding) is sensitive to earliest AD pathology circuits and correlates with p-tau biomarkers in cognitively unimpaired individuals, offering a scalable preclinical marker. The reader's strongest_claim and weakest_assumption accurately capture both the claim and its inherent limit (cross-sectional associations plus circuit plausibility do not yet equal proven prospective risk prediction). Because the attached full-text is a different paper, no deeper audit of citation quality, confound control, or overclaim is possible. Honest non-finding is therefore required: there is no new load-bearing concern beyond what the reader already identified. Verdict remains UNVERDICTED; agreement is full.","tokens_in":25547,"tokens_out":458,"duration_ms":5328,"concrete_test":"Retrieve the genuine full PDF of arXiv:2603.23082 and check whether the synthesis sections (evidence from biomarker-positive CU cohorts) report any prospective longitudinal prediction of clinical conversion, or only cross-sectional correlations; if only the latter appear, the abstract's 'will inform future interventions' claim stays aspirational and the reader's UNVERDICTED stance is confirmed.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The reader's weakest_assumption correctly flags that the abstract asserts navigation–biomarker correlations (path integration/wayfinding with p-tau) in cognitively unimpaired at-risk individuals and claims clinical utility for preclinical detection without new longitudinal outcome data. That is the natural soft spot for any narrative review of this type. However, the supplied CACHEABLE full-text block is the unrelated MedCausalX medical-VLM manuscript (arXiv 2603.23085), not the spatial-navigation review. No additional load-bearing technical flaw (e.g., mis-specified circuit mapping, unacknowledged confounds, or over-extrapolation of specific primary studies) can be verified or refuted from the actual body of 2603.23082. The concern therefore remains exactly the one the reader already stated; nothing stronger or more specific is supported by the available text.","agreement_with_reader":"agree"},"referee_report":{"model":"grok-4.5","summary":"This manuscript is submitted as a narrative review arguing that spatial navigation—especially path integration and wayfinding—is a particularly sensitive cognitive marker in preclinical Alzheimer’s disease. The abstract claims that navigation depends on circuits that are among the earliest sites of AD pathology, that performance on such tasks correlates with plasma and CSF AD biomarkers (notably p-tau) in cognitively unimpaired biomarker-positive individuals, and that navigation assessment could therefore provide a sensitive, scalable approach for early risk detection and for informing future interventions. The abstract further contrasts this putative early sensitivity with episodic memory decline, which is said to appear only after more substantial medial temporal damage.","tokens_in":25662,"tokens_out":918,"duration_ms":20927,"significance":"If the synthesis is accurate and the cited associations are robust after appropriate confound control and prospective validation, the review would be clinically and scientifically useful: it would consolidate a circuit-to-cognition rationale for navigation as a preclinical marker, highlight task classes (path integration, wayfinding) that may outperform standard memory tests at the asymptomatic stage, and motivate scalable digital or behavioral screening. That contribution would be of clear interest to cognitive neuroscience and AD biomarker communities. However, the significance of the present submission cannot be assessed from the materials provided, because the body text supplied under this arXiv ID does not correspond to the titled review.","major_comments":[{"comment":"The full manuscript text attached under paper_id 2603.23082 / title “Spatial navigation in preclinical Alzheimer’s disease: A review” is not that review. The body is an unrelated methods paper on MedCausalX (adaptive causal reasoning for medical vision–language models; arXiv 2603.23085), with its own abstract, CRMed dataset, reflective tokens, DPO/GRPO pipeline, and medical VQA tables. None of the promised content—overview of spatial navigation computations and tasks, mapping to earliest AD pathology sites, or synthesis of cognitively unimpaired biomarker-positive cohorts—is present. Peer review of the stated central claim is therefore impossible on the supplied file.","section":null},{"comment":"Even taking only the abstract of the intended review as the claim set, the load-bearing assertion that path integration and wayfinding performance “correlates with plasma and CSF biomarkers of AD pathology, notably p-tau” in cognitively unimpaired at-risk individuals, and that this “can represent a sensitive and scalable approach for early detection,” cannot be checked: there is no methods section defining inclusion criteria, no table of primary studies with effect sizes or quality appraisal, no discussion of confounds (age, vascular burden, education, task design, non-AD pathology), and no longitudinal outcome data supporting prospective risk prediction. Those elements are required for a review whose clinical recommendation rests on that correlation.","section":null},{"comment":"The abstract’s mechanistic premise—that navigation relies on neural circuits corresponding to the earliest sites of AD pathology and is therefore more sensitive than episodic memory—is a central organizing claim. Without the actual review body (circuit mapping, staging of pathology, and head-to-head comparison with memory measures in the same biomarker-defined cohorts), this premise remains an unexamined assertion rather than a documented synthesis.","section":null}],"minor_comments":[{"comment":"Abstract wording is generally clear, but “individuals at-risk of AD” should be defined more precisely (e.g., amyloid/tau biomarker criteria, genetic risk, or both) once the correct full text is available.","section":null},{"comment":"The abstract asserts clinical utility (“will inform future interventions”) without qualifying the current evidence level (cross-sectional association vs. prospective prediction). Softening that language until longitudinal data are reviewed would improve accuracy.","section":null}],"recommendation":"uncertain","confidential_remarks":"The submission package appears corrupted or mis-uploaded: title/abstract/arXiv ID point to a q-bio.NC narrative review on spatial navigation in preclinical AD, while the full text is a cs.AI medical VLM paper (MedCausalX). I cannot produce a content-level accept/reject decision on the navigation review until the correct manuscript is provided. Please request the authors (or production) to supply the matching full text and reassign for review. If the MedCausalX PDF was intentionally attached, the paper is out of scope for a neuroscience/AD review track and should be redirected."},"author_rebuttal":null,"desk_editor":{"model":"grok-4.5","letter":"Punchline: this is a narrative review arguing that spatial navigation—especially path integration and wayfinding—is more sensitive than episodic memory in preclinical AD because the circuits sit where pathology hits first, and that performance tracks plasma/CSF p-tau in cognitively unimpaired biomarker-positive people. If the body delivers a careful synthesis, that framing is clinically useful for trial enrichment and early risk work.\n\nWhat is actually new is limited, and that is fine for a review. There is no new primary experiment. The value is organization: mapping navigation computations and tasks onto early AD anatomy, then pulling together biomarker-positive unimpaired samples. The author list (Hornberger, Spiers, Coutrot, Garnier-Crussard and co.) is the right crowd for this literature, which raises the prior that the circuit story and task taxonomy will be competent rather than amateur.\n\nSoft spots, in proportion. First, practical: the full-text block supplied under this arXiv id is a different manuscript (MedCausalX, medical VLMs). So I cannot audit inclusion criteria, effect sizes, quality appraisal, or whether the p-tau claim is over-weighted relative to the primary studies. Confidence has to stay low until the real body is read. Second, the abstract’s natural soft spot—the same one any review of this type carries—is the jump from cross-sectional navigation–biomarker associations to “sensitive and scalable” preclinical detection and intervention guidance. Confounds (age, vascular load, education, task design, non-AD pathology) and the lack of new longitudinal outcome data are not disproved by the abstract; they are simply not settled by it. Circularity is not the issue; selective emphasis could be.\n\nWho it is for: people running AD prevention trials, cognitive-aging labs, and anyone choosing digital or VR navigation batteries for enrichment. Not a methods paper and not a first-principles result.\n\nRecommendation: if the real manuscript matches the abstract’s scope and cites the primary work fairly, it deserves a serious referee rather than a desk reject. I would not cite it from the abstract alone, and I would only bring it to reading group once we have the correct PDF and can check how hard they push the screening claim.","headline":"Useful narrative synthesis on navigation as a preclinical AD marker, but I only have the abstract—and the attached full text is the wrong paper—so treat claims about p-tau correlations and screening utility as still unchecked.","tokens_in":26315,"tokens_out":562,"would_cite":false,"duration_ms":20523,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"grok-4.5","headline":"Spatial navigation tasks can flag Alzheimer's risk years before memory symptoms, tracking early pathology biomarkers in people who still test as cognitively normal.","keywords":["preclinical Alzheimer's disease","spatial navigation","path integration","wayfinding","p-tau","biomarkers","early detection","medial temporal lobe"],"falsifier":"A prospective study in cognitively unimpaired biomarker-positive people showing that baseline path-integration or wayfinding scores do not predict later cognitive decline or conversion once age, vascular burden, education, and non-AD pathology are controlled.","tokens_in":26415,"feed_emoji":"🧭","tokens_out":709,"duration_ms":14582,"temperature":0.7,"pith_summary":"Alzheimer's disease builds quietly for years before memory tests fail. This review argues that spatial navigation—especially path integration and wayfinding—is hit earlier than episodic memory because it depends on the same brain circuits where AD pathology first appears. Drawing on studies of cognitively unimpaired people who already carry AD biomarkers, it shows that navigation performance lines up with plasma and CSF markers, notably p-tau. If that link holds, simple, scalable navigation tests could identify people at risk in the preclinical window and guide earlier interventions before clinically significant decline sets in.","feed_headline":"Navigation tests flag Alzheimer's risk before memory fails","feed_subtitle":"Path integration and wayfinding track p-tau and other biomarkers in people still scored as cognitively normal.","key_machinery":"The alignment of spatial navigation computations (path integration and wayfinding) with the neural circuits that are the earliest sites of AD pathology—used to explain why navigation measures can detect risk before episodic memory decline.","core_discovery":"In cognitively unimpaired individuals with AD biomarkers, performance on spatial navigation tasks—particularly path integration and wayfinding—correlates with plasma and CSF markers of AD pathology (notably p-tau), making navigation assessment a sensitive candidate for preclinical risk detection.","pith_inferences":["If navigation truly tracks earliest circuit failure, digital or VR path-integration tasks could become remote, low-cost screening tools outside specialty clinics.","Dissociating path integration from wayfinding may help separate entorhinal-centered from broader network contributions to early AD risk.","Combining navigation metrics with plasma p-tau could tighten enrichment of prevention trials beyond biomarkers alone."],"forward_implications":["Path integration and wayfinding tests could be added to preclinical screening batteries alongside or ahead of standard memory tests.","Plasma or CSF p-tau levels may be interpretable together with navigation scores as a joint early-risk signal.","Scalable navigation assessments could help select asymptomatic at-risk participants for prevention trials.","Interventions timed to navigation decline might slow progression before clinically significant impairment appears.","Future work should prioritize longitudinal designs that test whether navigation change predicts clinical outcomes."],"fun_headline_variants":["Spatial navigation tracks p-tau before memory fails","Path integration flags Alzheimer's risk in unimpaired adults","Wayfinding scores link to AD biomarkers preclinically","Navigation tests reveal early AD pathology via p-tau","Spatial path tasks mark preclinical Alzheimer's risk"],"cache_read_input_tokens":16512,"weakest_assumption_plain":"That the observed links between navigation scores and AD biomarkers in still-unimpaired people truly reflect early AD circuit damage, not age, vascular disease, education, task quirks, or other pathology—and that those links will predict future clinical decline.","fun_headline_variants_meta":{"raw":{"variants":["Spatial navigation tracks p-tau before memory fails","Path integration flags Alzheimer's risk in unimpaired adults","Wayfinding scores link to AD biomarkers preclinically","Navigation tests reveal early AD pathology via p-tau","Spatial path tasks mark preclinical Alzheimer's risk"]},"model":"grok-4.5","effort":"low","cost_usd":0.003984,"raw_usage":{"total_tokens":1144,"prompt_tokens":720,"num_sources_used":0,"completion_tokens":58,"cost_in_usd_ticks":39840000,"prompt_tokens_details":{"text_tokens":720,"audio_tokens":0,"image_tokens":0,"cached_tokens":0},"completion_tokens_details":{"audio_tokens":0,"reasoning_tokens":366,"accepted_prediction_tokens":0,"rejected_prediction_tokens":0}},"tokens_in":720,"tokens_out":58,"duration_ms":3311,"temperature":1.0,"reasoning_tokens":366,"cache_read_input_tokens":0,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-07-13T19:52:31.230461+00:00","model_set":{"reader":"grok-4.5"},"falsifier":"A prospective study in cognitively unimpaired biomarker-positive people showing that baseline path-integration or wayfinding scores do not predict later cognitive decline or conversion once age, vascular burden, education, and non-AD pathology are controlled.","supporting_citations":[],"review_version":1}